eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study

Inna Danilycheva
1
,
Alexander Emelyanov
2
,
Raisa Meshkova
3
,
Olga Ukhanova
4
,
Azat Abdrakhmanov
5
,
Loliana Litvin
6

1.
Department of Allergology and Immunotherapy, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
2.
Department of Respiratory Medicine and Allergy, North-Western Medical University, Saint Petersburg, Russia
3.
Department of Clinical Immunology and Allergology, State Medical University, Smolensk, Russia
4.
State Budgetary Healthcare Institution of Stavropol Territory, Stavropol Regional Clinical Hospital, Stavropol, Russia
5.
Department of Dermatovenereology, Kazan State Medical University, Kazan, Russia
6.
Novartis Pharma LLC, Moscow, Russia
Adv Dermatol Allergol 2022; XXXIX (3): 509-516
Online publish date: 2022/07/14
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Data on burden and treatment outcomes of chronic spontaneous urticaria (CSU) in Russia are limited. Poor adherence to recommended treatments can lead to suboptimal management of CSU patients. Aim: To understand disease burden, treatment algorithms, and outcomes of CSU in the Russian cohort of the AWARE study.

Material and methods
AWARE was a global prospective, non-interventional study of chronic urticaria in the real-world setting. Adult patients with H1-antihistamines (H1AH)-refractory CSU for ≥ 2 months were included. Disease characteristics, quality of life (QoL), healthcare resource utilisation (HRU), and pharmacological treatments were observed during the 2-year study period.

Results
Of the 135 patients enrolled from Russia, 121 completed the study. Pre-baseline, ~37% of patients were managed with non-recommended treatments (33% treated with sedative H1AH; 4% with other non-recommended treatments) and 28.2% of patients were not treated for CSU. There was a reduction in the use of sedative H1AH during the study (0.9% of patients treated with sedative H1AHs at Year 2). Decreased disease activity was seen as early as 3 months and continued to improve over 2 years (Urticaria Activity Score over 7 days (UAS7): 20.2 at baseline (n = 124) to 10.1, 7.1, and 3.2 at month 3 (n = 118), 12 (n = 109), and 24 (n = 109), respectively). This corresponded with QoL improvements (dermatology life quality index (DLQI) score: 10.3 at baseline to 5.4, 3.6, and 2.3 at Month 3 (n = 75), 12 (n = 98), and 24 (n = 92), respectively), and reduced angioedema and hives throughout the study.

Conclusions
The burden of CSU in Russia is high, contributing to increased HRU. Guideline-recommended treatments and systematic escalation of therapy to achieve complete symptom control can improve management of patients with CSU.

keywords:

angioedema, AWARE, epidemiology, quality of life, treatment guidelines, urticaria

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.